Previous close | 459.10 |
Open | 451.70 |
Bid | 443.50 x 100000 |
Ask | 444.00 x 100000 |
Day's range | 443.30 - 451.70 |
52-week range | 365.90 - 536.80 |
Volume | |
Avg. volume | 5 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WESTBROOK, Maine, June 24, 2024--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 second quarter results for Tuesday, August 6, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the Catalyst® Pancreatic Lipase Test, a single-slide solution for canine and feline patients suspected of pancreatitis. With the innovative load-and-go workflow of the Catalyst analyzers, the test can run effortlessly alongside chemistry profiles, leading to a faster path to diagnosis and enhanced patient outcomes. The Catalyst Pancreatic Lipase Test will be available in the U.S. and Ca
WESTBROOK, Maine, May 14, 2024--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon, Executive Vice President and Chief Financial Officer, and Michael Lane, Executive Vice President, General Manager, Reference Laboratories and Information Technology, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 29, 2024 from 10:55 am – 11:25 am (EDT).